title: Expression of immune checkpoints in T cells of esophageal cancer patients.
abstract: Inhibition of immune checkpoint proteins (checkpoints) has become a promising anti-esophageal cancer strategy. We here tested expressions of immune checkpoints in human esophageal cancers. Our results showed the expressions of many immune checkpoints, including CD28, CD27, CD137L, programmed death 1 (PD-1), T cell immunoglobulin mucin-3 (TIM-3), T cell Ig and ITIM domain (TIGIT), CD160, cytotoxic T lymphocyte antigen 4 (CTLA-4), CD200, CD137 and CD158, were dysregulated in peripheral T cells of esophageal cancer patients. Further, the expressions of PD-1, TIM-3 and TIGIT were upregulated in tumor infiltrating lymphocytes (TILs), which might be associated with TILs exhaustion. Meanwhile, the expressions of PD-1 and TIM-3 on CD4+ T cells were closely associated with clinic pathological features of esophageal cancer patients. These results indicate that co-inhibitory receptors PD-1, TIM-3 and TIGIT may be potential therapeutic oncotargets for esophageal cancer.
authors: Cancer Center, Hai'an Hospital Affiliated to Nantong University, Hai'an, China.
authors: Jinhua
authors: J
authors: Xie
authors: Department of Oncology, the Second Affiliated Hospital of Soochow University, Suzhou, China.
authors: Ji
authors: J
authors: Wang
authors: The Central Laboratory, Hai'an Hospital Affiliated to Nantong University, Hai'an, China.
authors: Shouliang
authors: Sh
authors: Cheng
authors: The Central Laboratory, Hai'an Hospital Affiliated to Nantong University, Hai'an, China.
authors: Liangfeng
authors: L
authors: Zheng
authors: The Central Laboratory, Hai'an Hospital Affiliated to Nantong University, Hai'an, China.
authors: Feiyue
authors: F
authors: Ji
authors: Cyrus Tang Hematology Center, Soochow University, Suzhou, China.
authors: Lin
authors: L
authors: Yang
authors: Cancer Center, Hai'an Hospital Affiliated to Nantong University, Hai'an, China.
authors: Yan
authors: Y
authors: Zhang
authors: Cancer Center, Hai'an Hospital Affiliated to Nantong University, Hai'an, China.
authors: Haoming
authors: H
authors: Ji
mesh_terms: D000368:Aged; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D060908:CTLA-4 Antigen / Q000378:metabolism; D016022:Case-Control Studies; D059447:Cell Cycle Checkpoints; D004938:Esophageal Neoplasms / Q000235:genetics / Q000276:immunology*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D000072597:Hepatitis A Virus Cellular Receptor 2 / Q000378:metabolism; D006801:Humans; D007107:Immune System / Q000502:physiology*; D007167:Immunotherapy; D008213:Lymphocyte Activation; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008297:Male; D008875:Middle Aged; D061026:Programmed Cell Death 1 Receptor / Q000378:metabolism; D011971:Receptors, Immunologic / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology*; D015854:Up-Regulation
chemical_list: D060908:CTLA-4 Antigen; C448908:HAVCR2 protein, human; D000072597:Hepatitis A Virus Cellular Receptor 2; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D011971:Receptors, Immunologic; C534712:TIGIT protein, human
keywords: PD-1; TIM-3; cancer immunotherapy; esophageal cancer; immune checkpoints